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Background: The incidence of Acute Megakaryoblastic Leukemia (AMKL) is 500-fold higher in children with Down
Syndrome (DS) compared with non-DS children, but the relevance of trisomy 21 as a specific background of AMKL
in DS is still an open issue. Several Authors have determined gene expression profiles by microarray analysis in DS
and/or non-DS AMKL. Due to the rarity of AMKL, these studies were typically limited to a small group of samples.
Methods: We generated integrated quantitative transcriptome maps by systematic meta-analysis from any available
gene expression profile dataset related to AMKL in pediatric age. This task has been accomplished using a tool recently
described by us for the generation and the analysis of quantitative transcriptome maps, TRAM (Transcriptome Mapper),
which allows effective integration of data obtained from different experimenters, experimental platforms and data
sources. This allowed us to explore gene expression changes involved in transition from normal megakaryocytes
(MK, n=19) to DS (n=43) or non-DS (n=45) AMKL blasts, including the analysis of Transient Myeloproliferative Disorder
(TMD, n=20), a pre-leukemia condition.
Results: We propose a biological model of the transcriptome depicting progressive changes from MK to TMD and
then to DS AMKL. The data indicate the repression of genes involved in MK differentiation, in particular the cluster on
chromosome 4 including PF4 (platelet factor 4) and PPBP (pro-platelet basic protein); the gene for the mitogen-activated
protein kinase MAP3K10 and the thrombopoietin receptor gene MPL. Moreover, comparing both DS and non-DS AMKL
with MK, we identified three potential clinical markers of progression to AMKL: TMEM241 (transmembrane protein 241)
was the most over-expressed single gene, while APOC2 (apolipoprotein C-II) and ZNF587B (zinc finger protein 587B)
appear to be the most discriminant markers of progression, specifically to DS AMKL. Finally, the chromosome 21 (chr21)
genes resulted to be the most over-expressed in DS and non-DS AMKL, as well as in TMD, pointing out a key role of
chr21 genes in differentiating AMKL from MK.
Conclusions: Our study presents an integrated original model of the DS AMLK transcriptome, providing the
identification of genes relevant for its pathophysiology which can potentially be new clinical markers.
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Trisomy for human chromosome 21 (chr21) is the most
frequent live-born aneuploidy and is the cause of Down
syndrome (DS), whose main symptoms include intellec-
tual disability, cardiovascular defects and craniofacial
dysmorphisms [1]. The DS phenotype is thought to be
associated with an altered expression of the genes lo-
cated on chr21 [2-7]. Basic research on DS is now rap-
idly accelerating, and there is the possibility that the
results will be beneficial for individuals with DS [8].
Several studies have shown that individuals with DS have
a specific cancer risk pattern, or tumor profile: their risk of
developing leukemia and testicular cancer is much higher
than age-matched controls, while women with DS almost
never develop breast cancer [9,10]. In particular, children
with DS show an increased prevalence of acute leukemia,
both lymphoid (ALL) and myeloid (AML), with relative
risk ranging from 10 to 20 times higher than the normal
population [11,12]. In nearly half of the cases, these child-
hood leukemias are classified as megakaryoblastic leukemia
(AMKL), a relatively rare subtype of AML also known as
AML M7, according to French–American–British (FAB)
classification, whose incidence increases by 500-fold in
children with DS by the age of 4 years as compared to the
chromosomally normal population (reviewed in [13]). This
observation strongly suggests that trisomy 21 directly con-
tributes to the neoplastic transformation of hematopoietic
cells, in particular in the megakaryocyte lineage cells. Inter-
estingly, acute leukemia cells harboring megakaryocyte
markers and presenting in subjects without DS may show
trisomy 21 [14]. We also described a cell line derived from
blast cells of a patient with type M2 AML which has tri-
somy 21 and megakaryocyte features [15]. More recently,
mutations of the gene encoding for the transcription factor
GATA1 have been shown to cooperate with trisomy 21 in
initiating megakaryoblastic proliferation in nearly all DS
AMKL cases while they are absent in non-DS AMKL
[13,16]. GATA1 mutations in DS cells give rise to a short,
truncated form of GATA1 (GATA1s) transcription factor
that, in this form, is not able to establish normal interac-
tions with other gene regulators [17].
Transient myeloproliferative disorder (TMD) is a clonal
pre-leukemia condition, occurring in 10% of children with
DS during the neonatal period, presenting at a median age
of 3-7 days with accumulation of immature megakaryo-
blasts [13]. TMD cases usually resolve spontaneosuly, but
DS AMKL may develop within 1-4 years in 20-30% of these
children. AMKL may develop in non-DS children, usually
at an higher age in comparison to DS subjects (median 8
vs. 1.8 years, respectively) and in absence of a trisomy 21
background. Cytogenetic abormalities described in non-DS
AMKL cells include trisomy 8 and 1 and monosomy 7 [13].
An open issue is the relevance of trisomy 21 as a specific
background for the higher incidence of AMKL in DS. Afew previous studies have used gene expression profiling
by microarray analysis in order to identify specific tran-
scriptome alterations in DS and/or non-DS AMKL, as well
as in TMD [17-24]. Due to the rarity of AMKL, these
works often analyze a small number of cases, using a var-
iety of experimental platforms. Results were consequently
affected by a small grade of comparability.
One of the first goals of this work was to perform a sys-
tematic meta-analysis using any available gene expression
profile dataset related to AMKL in pediatric age in order
to produce a differential transcriptome map between DS
and non-DS related AMKL. This task has been accom-
plished using a tool recently described by us for the gener-
ation and the analysis of quantitative transcriptome maps,
TRAM (Transcriptome Mapper) [25], which allows effect-
ive integration of data obtained from different experi-
menters, experimental platforms and data sources. The
comparison of 43 DS AMKL samples with 45 non-DS
AMKL samples represents the largest study on the sub-
ject, highlighting the relevance of trisomy 21 in the devel-
opment of AMKL in comparison with AMKL originating
from non-trisomic cells. Results show significant over- or
under-expression of distinct chromosomal segments and
of single key genes in the whole genome, as well as on
chr21, adding new knowledge compared with that pro-
duced by the single works from which the data were ori-
ginally obtained. In addition, each considered type of
leukemia was compared with the expression profile of
TMD cells and normal human megakaryoblast/megakar-
yocyte cells (MK), allowing the building of a model for the
disorder in differentiation process that lead to DS and
non-DS AMKL. Comparisons with cord blood-derived
MK cells (CB MK) have also been performed, due to the
fact that leukemias in infants or young children originate
from fetal hematopoietic cells [17,18,26,27] and the pro-
genitor cells (fetal/neonatal MKP) are present in the cord
blood (CB) [28,29].
For each cell type investigated, reference expression
data for about 17,000-26,000 mapped sequences have
been generated and validated through a sample compari-
son with known data. The biological and clinical signifi-
cance of these data is discussed.
Methods
Literature search
A systematic biomedical literature search was performed
up to January 2013 in order to identify articles related to
global gene expression profile experiments in AMKL pa-
tients (DS AMKL, non-DS AMKL and TMD conditions).
A general search using the commonly used acronym
"AMKL" retrieved 157 articles.
The MeSH term "Leukemia, Megakaryoblastic, Acute"
was also used for a PubMed search in the expression:
"Leukemia, Megakaryoblastic, Acute"[Mesh] AND ("Gene
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Sequence Analysis"[Mesh] OR "Microarray Analysis"[Mesh]
OR microarray* OR "Expression profile" OR SAGE).
Database search
Gene Expression Omnibus (GEO) [30] functional genom-
ics repository was searched for: (AMKL[All Fields] OR
(AML[All Fields] AND M7[All Fields])) AND "Homo
sapiens"[Organism]. A more general search using the ex-
pression "Down Syndrome"[MeSH] AND "Homo sapiens"
[Organism] was also used.
ArrayExpress database [31] of functional genomics exper-
iments was searched for the terms: ''AMKL'', "Megakaryo-
blastic", "AML M7".
In order to obtain gene expression profile datasets for
normal human MK cells, in addition to the 9 used in
the original description of the TRAM software [25], we
searched GEO for the expression ("Megakaryocytes"
[Mesh] OR Megakaryoblast*) AND "Homo sapiens"
[ORGANISM]. The ArrayExpress database was searched
for the expressions "Megakaryocyte", "Megakaryocytic",
"Megakaryoblast", "MK".
The searches were performed up to January 2013.
Dataset selection
The inclusion criteria of datasets in the analysis were:
availability of the raw or pre-processed data; pediatric
age of the subject from whom the sample was obtained;
diagnosis of DS or non-DS AMKL or TMD.
Exclusion criteria were: exon arrays (hampering data
elaboration by TRAM due to exceedingly high number of
data rows) or platforms using probes split into several dis-
tinct arrays for each sample (hampering intra-sample
normalization); lack of identifiers corresponding to those
found in the GEO sample records (GSM) or ArrayExpress
sample records; platforms assaying an atypical number of
genes (i.e. <5.000 or >60.000); cell line derived data; spe-
cific subtype of non-DS AMKL, e.g. t(1;22); trisomy 21 in
non-DS AMKL samples.
Normal MK samples were considered for the analysis
when fulfilling these criteria: late MK colonies (10-14
days) or MK sorted cells, obtained from peripheral blood
(PB), bone marrow (BM) or cord blood (CB). MK cul-
tured for less than 10 days or Colony Forming Unit-
Megakaryocytic (CFU-MK) were excluded.
In order to obtain a quantitative transcriptome map,
values from each dataset were linearized when provided
as logarithms. In some cases we used raw files (e.g. File
CEL) to be converted into pre-processed data, using the
software "Alt Analyze" [32].
TRAM (transcriptome mapper) analysis
TRAM (Transcriptome Mapper) software [25] allows the
import of gene expression data recorded in the NCBI(National Center for Biotechnology Information) GEO and
EBI (European Bioinformatics Institute) ArrayExpress data-
bases in tab-delimited text format. It also allows the inte-
gration of all data by decoding probe set identifiers to gene
symbols via UniGene data parsing [33], normalizing data
from multiple platforms using intra-sample and inter-
sample normalization (scaled quantile normalization) [34],
creating graphical representation of gene expression profile
through two ways, "Map" and "Cluster" mode, and deter-
mining the statistical significance of results. Moreover,
TRAM allows to compare two biological conditions identi-
fying critical genomic regions and genes with significant
differential expressions.
We created a directory (folder) for each condition,
containing all the sample datasets related to the same
source and selected for the study: DS AMKL (pool 'A');
non-DS AMKL (pool 'B'); TMD (pool 'C'); normal MK
(pool 'D'); normal CB MK (pool 'E').
We ran the whole set of analyses permitted by TRAM
(in both "Map" and "Cluster" mode, although we focused
on the "Map" mode) using default parameters as de-
scribed [25]. We used an updated version of TRAM in-
cluding enhanced resolution of gene identifiers and
updated UniGene and Entrez Gene databases (TRAM
1.1, June 2013), in comparison with the original 2011
version [25]. When the gene location cytoband was not
available in the Gene database [35], it was manually de-
rived from UCSC Genome Browser [36]. TRAM is freely
available at http://apollo11.isto.unibo.it/software. Briefly,
gene expression values were assigned to individual loci
via UniGene, intra-sample normalized as percentage of
the mean value and inter-sample normalized by scaled
quantile. The value for each locus, in each biological
condition, is the mean value of all available values for
that locus. The genome wide gene expression median
value was used in order to determine percentiles of ex-
pression for each gene.
Using the "Map" mode graphical representation we
searched for over/under-expressed genome segments,
which have a window size of 500,000 bp and a shift of
250,000 bp. The expression value for each genomic seg-
ment is the mean of the expression values of the loci
included in that segment. A segment is defined over/
under-expressed if it has an expression value which is sig-
nificantly different between two conditions analyzed, and
contains at least 3 individually over/under-expressed genes,
e.g. genes which have expression values within the highest
and the lowest 2.5th percentile. Significance of the over/
under-expression for single genes was determined by run-
ning TRAM in "Map" mode with a segment window of
12,500 bp. This window size corresponds to about a quar-
ter of the mean length of a gene, so the significant over/
under-expression of a segment almost always corresponds
with that of a single gene. A segment or a gene was
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expressed for q < 0.05, where q is the p-value obtained by
the method of hypergeometric distribution [25] and cor-
rected for multiple comparison. When the segment win-
dow contains more than one gene, the significance is
maintained if the expression value of the over/under-
expressed gene prevails over the others.
For the creation of the maps, TRAM software does
not consider probes where the expression values is not
available, assuming that an expression level has not been
measured. Furthermore, it gives 95% of the minimum
positive value present in a sample to those expression
values equal to or lower than "0", in order to obtain
meaningful numbers when we need to obtain a ratio be-
tween values in pool 'A' and pool 'B'. Assuming that in
these cases an expression level is too low to be detected
under the experimental conditions used, this transform-
ation is useful to highlight differential gene expression.
Finally, we considered the most over- or under-
expressed genes among the genes associated with at least
5 data points.
At chromosomal level, we calculated (in the TRAM
"chr" table) the median expression ratio for all the genes
located in the same chromosome.
Other analysis
FuncAssociate analysis [37] was used to obtain Gene
Ontology attributes in order to functionally characterize
large sets of genes derived from the TRAM analysis.
Results
Literature search
A general search using the acronym ''AMKL'' retrieved
157 articles, 6 of them describe gene expression profiling
experiments [17,18,20-23].
No additional pertinent item was retrieved using the ex-
pression described in the Methods section and including
the MeSH Term "Leukemia, Megakaryoblastic, Acute".
Database search
The Gene Expression Omnibus (GEO) [30] search allowed
the retrievement of three additional works describing data
possibly useful for meta-analysis [19,24,38]. The lack of in-
clusion of these works in the literature search was due to
failure of using the ''AMKL'' acronym and assigning the
MeSH Term "Leukemia, Megakaryoblastic, Acute" during
the PubMed indexing process (the more general term
"Leukemia, Myeloid, Acute" was used).
The more general search using the expression "Down
Syndrome"[MeSH] AND "Homo sapiens"[Organism]
allowed the addition of one further work [39]. This work
analyzed several types of AML samples and did not ex-
plicitly mention AMKL or AML M7 in both PubMed
and GEO databases.No further pertinent works related to AMKL were
identified by ArrayExpress database [31] search.
Several datasets for normal MK cells global gene ex-
pression profile fulfilling the selection criteria were ob-
tained from the works [40] (GEO, 7 samples) and [41]
(ArrayExpress, 1 sample), in addition to the 4 sample
series identified in the first report of the TRAM software
[25] and obtained from different works [42-45], for a
total of 19 datasets related to human normal MK cells.
Dataset building
Of the 10 works related to DS or non-DS AMKL retrieved
as above described, 7 were considered for the meta-analysis
(Table 1). It was not possible to obtain raw data from the
Authors of [20], while the only sample of AML M7 de-
scribed in [38] was related to "Leukemic Stem Cells" cell
type and the two AML M7 reported by Tomasson et al.
[39] were obtained from elderly patients. Raw data from [23]
were kindly provided by Drs. Jeffrey Taub and Yubin Ge.
At the end, DS AMKL sample pool 'A' included 43
datasets, while non-DS AMKL sample pool 'B' was com-
posed of 45 datasets. A TMD dataset pool 'C' was con-
structed starting from 20 samples described in some of
the DS AMKL related articles [18,21,22]. Age and sex
data were available for 29 out of 43 DS AMKL patients
(mean age: 20 months; 11 males and 18 females), for 26
out of 45 non-DS AMKL patients (mean age: 19 months;
19 males and 7 females) and for 9 out of 20 TMD pa-
tients (mean age: 8 days; 7 males and 2 females). GATA1
mutations giving rise to GATA1s were present in all DS
AMKL and TMD samples, and not in non-DS AMKL
samples, considering all samples for which this informa-
tion was provided. Sample identifiers and main sample
features are listed in Table 1 and Additional file 1 (avail-
able at: http://apollo11.isto.unibo.it/suppl).
Two pools were constructed from the normal MK
related dataset selected: pool 'D' included all available
MK samples, while pool 'E' was a subset including only
CB-derived MK cells (Table 1 and Additional file 1).
Transcriptome differential maps
Datasets were loaded into TRAM and analyzed obtain-
ing 8 transcriptome maps: DS AMKL (pool 'A') vs. non-
DS AMKL (pool 'B'); DS AMKL (pool 'A') vs. normal
MK (pool 'D'); non-DS AMKL (pool 'B') vs. normal MK
(pool 'D'); DS AMKL (pool 'A') vs. normal CB MK (pool
'E') cells; non-DS AMKL (pool 'B') vs. normal CB MK
(pool 'E'); DS AMKL (pool 'A') vs. TMD (pool 'C'); TMD
(pool 'C') vs. normal MK (pool 'D'); TMD (pool 'C') vs.
normal CB MK (pool 'E').
For each comparison between two cell types by TRAM,
we describe below or in the corresponding Figures or
Tables the total of data points analyzed for each cell type,
i.e. gene expression values for all human mapped loci
Table 1 Main features of the samples used in TRAM analyses
Study ID Sample ID Sample type Platform Microarray Spots References
Pool 'A' (n=43) - DS AMKL (25,955 mapped loci following analysis by TRAM)
A1…A3 (n=3) GSM491372…4 BM Sorted leukemic blasts GPL570 Affymetrix U133 Plus 2.0 54,675 [18]
A4…A25 (n=22) GSM94245, GSM94272…92 BM or PB GPL96 Affymetrix U133A 22,283 [22]
A26…A31 (n=6) GSM417985…90 BM or PB Sorted leukemic blasts GPL570 Affymetrix U133 Plus 2.0 54,675 [17]
A32…A38 (n=7) E-MEXP-72* BMMC or PBMC A-AFFY-33.adf.txt* Affymetrix U133A 22,283 [21]
A39…A43 (n=5) / BMMC or PBMC GPL96 Affymetrix U133A 22,283 [23]
Pool 'B' (n=45) - non-DS AMKL (26,045 mapped loci following analysis by TRAM)















BM or PB GPL96 Affymetrix U133A 22,283 [24]
B36…B40 (n=5) GSM417991…5 BM or PB Sorted leukemic blasts GPL570 Affymetrix U133 Plus 2.0 54,675 [18]
B41…B45 (n=5) / BMMC or PBMC GPL96 Affymetrix U133A 22,283 [23]
Pool 'C' (n=20) - TMD (25,955 mapped loci following analysis by TRAM)
C1…C3 (n=3) GSM491375…7 BM Sorted leukemic blasts GPL570 Affymetrix U133 Plus 2.0 54,675 [18]
C4…C11 (n=8) GSM94293…9, GSM94300 BM or PB GPL96 Affymetrix U133A 22,283 [22]
C12…C20 (n=9) E-MEXP-72* BMMC or PBMC A-AFFY-33.adf.txt* Affymetrix U133A 22,283 [21]
Pool 'D' (n=19) - MK (26,372 mapped loci following analysis by TRAM)
D1-D2 (n=2) GSM321577-8 MK (BM) (subj = pool) GPL96 Affymetrix U133A 22,283 [45]
D3…D6 (n=4) GSM112277-8, GSM112291-2 MK (PB) (subj = 1, rep. 1) GPL887 Agilent 1A 22,575 [44]
D7-D8 (n=2) GSM15648, GSM8649 MK (BM) (subj = 6) GPL96 Affymetrix U133A 22,283 [42]
D9…D11 (n=3) GSM88014-22-34 MK (PB) (subj = 1) GPL887 Agilent 1A 22,575 [43]
D12…D18 (n=7) GSM609746…52 CB GPL4685 Affymetrix HT-HG_U133A 22,944 [40]
D19 (n=1) E-MEXP-2146* CB A-AFFY-44.adf.txt Affymetrix U133 Plus 2.0 54,675 [41]
Pool 'E' = D12…D19 (n=8) - CB MK (25,577 mapped loci following analysis by TRAM)
Samples selected for the meta-analysis of gene expression profiles in DS AMKL (pool 'A'), non-DS AMKL (pool 'B'), TMD (pool 'C'), and megakaryocytic cells (pool
'D' and 'E'). All Sample IDs and Platforms IDs are related to GEO database, other than codes marked with * (ArrayExpress database). Sample type: BM, bone
marrow; PB, peripheral blood; BMMC, bone marrow mononuclear cells; PBMC, peripheral blood mononuclear cells; MK, megakaryocytic/megakaryoblast cells,
obtained by in vitro differentiation of CD34+ cells; CD34+, undifferentiated CD34+ cells; BM, CB or PB: CD34+ cells derived from bone marrow, cord blood or
peripheral blood, respectively. subj = number of subjects from which the sample was derived (in some cases, where subj = pool, the exact number of subjects
included in a pool was not available). rep. = biological replicate. Microarray: U133A: Affymetrix Human Genome U133A Array; 1A: Agilent-012097 Human 1A
Microarray (V2) G4110B; 22k A: Agilent Human oligo 22k A; HG-Focus: Affymetrix Human HG-Focus Target Array.
Details about Sample identifiers and main sample features are listed in Additional file 1 (available at: http://apollo11.isto.unibo.it/suppl).
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number of loci for which the comparison between the two
conditions was possible due to the presence of values for
those loci in both sample pools considered; the number
and the gene content of each genomic segment containing
at least three over- or under-expressed genes and found to
be statistically significantly over- or under-expressed in
the comparison between the two tissues. Each genomic seg-
ment was identified among the 12,373 segments generatedusing the default window of 500,000 bp with a sliding win-
dow of 250,000 bp and following removal of overlapping
segments with similar gene content. When the results
were reported for the over/under-expressed single genes,
we considered only the genes associated at at least 5 data
points.
The description of the gene name corresponding to all
gene symbols cited here in the text, Figures or Tables is
given in the Additional file 2. We performed a PubMed
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genes using gene symbol or gene description along with
MeSH terms related to MK or MK progenitor cells,
thrombopoiesis, AMKL, platelets.
Detailed results for each map are provided below, and
are also available at: http://apollo11.isto.unibo.it/suppl.
The absolute (not differential) expression values and
maps for each cell type (not compared to another cell
type) are also available in the complete sets of results at
http://apollo11.isto.unibo.it/suppl, but are not discussed
here because they include typical housekeeping genes
whose over-expression is no longer evident when com-
pensated by the corresponding housekeeping genes in
the compared cell type.
Transcriptome map comparison of DS AMKL vs. non-DS
AMKL
We first analyzed regional differential expression of pool
'A' (43 DS AMKL samples) versus pool 'B' (45 non-DS
AMKL samples) (Table 1). A total of 1,061,761 dataFigure 1 Main results of DS AMKL vs. MK, DS AMKL vs. non-DS AMK,
number of loci analyzed, the most over- or under-expressed segments and
all the genes located in the same chromosome are indicated.points from the pool 'A' and 1,084,700 data points from
the pool 'B' were included in the analysis. An 'A'/'B' ratio
value was determinable for 25,954 loci having values both
in 'A' and 'B' pools (Additional file 3). The main results are
shown in Figure 1. Results obtained by the analysis in-
cluded 3 significantly non-overlapped over-expressed seg-
ments (Table 2a). The highest expression ratio between
DS AMKL and non-DS AMKL (3.27) was observed in a
segment on chromosome 15 (15q21.2), including the
known gene HDC (encoding for histidine decarboxylase,
which converts L-histidine to histamine). The second seg-
ment with the highest expression was located on chromo-
some 4 (4q31.1) and contained over-expressed genes such
as GYPE, GYPB and GYPA, encoding for glycophorin E, B
and A (MNS blood group) respectively. The third over-
expressed segment spans the cluster of apolipoprotein
encoding genes on chromosome 19 (19q13.2).
At single gene level, a fold increase higher than 5 was
observed in all of the first 20 genes with the greatest ex-
pression ratios of DS AMKL vs. non-DS AMKL samplesnon-DS AMKL vs. MK comparisons. For each comparison the
single genes, and the highest and lowest median expression ratios for
Table 2 Genomic segments significantly over- or under-expressed
a) DS AMKL vs. non-DS AMKL






q-value Genes in the segmentc
Over-expressed segments
chr15 15q21.2 50,250,001 50,750,000 3.27 0.00233 ATP8B4- SLC27A2+ HDC+ GABPB1+ FLJ10038+ GABPB1-AS1+
Hs.656448+ Hs.660869+d USP8+
chr4 4q31.1 144,750,001 145,250,000 2.21 0.00024 GYPE+ Hs.658686- GYPB+ GYPA+
chr19 19q13.2 45,000,001 45,500,000 1.58 0.00461 ZNF180- PVR+ CEACAM19- BCL3+ CBLC+ BCAM+ PVRL2- Hs.666142-
TOMM40+ APOE+ APOC1+ APOC4+ APOC2+ CLPTM1+
b) DS AMKL vs. MK






q-value Genes in the segment
Over-expressed segments
chr3 p26.2 3,500,001 4,000,000 20.81 0.00006 Hs.241414+ Hs.587205+ LRRN1+ Hs.128128+
chr1 1q23 166,000,001 166,500,000 18.07 0.00004 Hs.22930+ FAM78B+ Hs.662048+
chr15 15q26.2 96,750,001 97,250,000 14.73 0.00001 Hs.677040+ Hs.661950+ NR2F2-AS1+ NR2F2- Hs.592015+
Under-expressed segments
chr4 4q12-q21 74,750,001 75,250,000 0.45 0.00079 PF4- PPBP- CXCL5- CXCL3- CXCL2- MTHFD2L- Hs.662627- EREG-
chr4 4q32.1 156,250,001 156,750,000 0.13 0.00012 MAP9- GUCY1A3- Hs.612374- GUCY1B3-
c) Non-DS AMKL vs. MK






q-value Genes in the segment
Over-expressed segments
chr15 15q26.2 96,750,001 97,250,000 22.30 <0.00001 Hs.677040+ Hs.661950+ NR2F2-AS1+ NR2F2- Hs.592015+
Under-expressed segments
chr4 4q13-q21 74,500,001 75,000,000 0.39 0.00009 IL8- CXCL6- PF4V1- CXCL1- PF4- PPBP- CXCL5- CXCL3- CXCL2-
Data refer to the following comparisons: a) DS AMKL (pool 'A') vs. non-DS AMKL (pool 'B'); b) DS AMKL (pool 'A') vs. MK (pool 'D'); c) non-DS AMKL (pool 'B') vs.
MK (pool 'D'). Analysis was performed using default parameters (see Methods section). Segments are sorted by decreasing 'A'/'B' ratio in a), 'A'/'D' ratio in b), 'B'/'D'
ratio in c). In the "Map" mode, TRAM displays UniGene EST clusters (with the prefix "Hs." in the case of Homo sapiens) only if they have an expression value. Some
segments are not shown for simplicity because they are over-lapping with those highlighted in one of the listed regions. The complete results for these models
are available as on line additional material.
aChr: chromosome. The segment location cytoband was derived from that of the first mapped gene within the segment.
bSegment Start/End: chromosomal coordinates for each segment.
cBold and '+': over-expressed gene; bold and '-': under-expressed gene; '+' or '-': gene expression value higher or lower than the median value, respectively.
dThis UniGene cluster contains EST with at least one Alu sequence, according to Repeat Masker [46]. For this reason, it can not be excluded that its over-expression is
related to unspecific hybridization by Alu-containg probes.
Pelleri et al. BMC Medical Genomics  (2014) 7:63 Page 7 of 22(Table 3a and Additional file 3). In particular, a 24-fold
increase was observed for SLITRK6 gene, encoding for a
membrane protein to date described as similar to recep-
tor for BDNF (brain-derived neurotrophic factor) and
predominantly expressed in neural tissues. Among the
genes with the lower 'A'/'B' expression ratios a 169.5-fold
decrease was observed for a UniGene EST cluster,
Hs.355689.
At chromosomal level, we calculated (in the TRAM
"Chr" table) the median 'A'/'B' expression ratio for all
the genes located in the same chromosome. The
highest ratios were near to 1 (0.93 for chr22, 0.92
for chrX and chr21, 0.91 for chr19); other values
were in the range from 0.90 (chr17 and chr12) to
0.76 (chrY).We performed two additional transcriptome maps to in-
vestigate specifically sex-biased gene expression patterns
(data not shown, results may be regenerated by the user
by excluding/including or reimporting samples on the
basis of data provided in Additional file 1): in particular,
we compared male (pool 'A.1', n=11) vs. female DS AMKL
cells (pool 'A.2', n=18). These datasets are derived
from the samples for which the knowledge about the sex
of the sample donor was available. The results showed a
significant statistical correlation of data between male and
female gene expression data (r=0.99, p-value<0.0001),
showing a large overlap of results between the two tran-
scriptome maps, with the exception of single genes with a
well known sex-biased expression pattern. For example,
XIST, which is specifically activated in female cells to start
Table 3 List of the five most over- or under-expressed genes (all significantly, with q < 0.05)
a) DS AMKL vs. non-DS AMKL
Gene Value 'A' Value 'B' 'A'/'B' ratio Location Data points SD SD
'A' 'B' 'A' 'B'
Over-expressed genes
SLITRK6 465.5 19.5 23.860 13q31.1 27 21 113.0 79.6
HDC 1,119.4 65.5 17.097 15q21-q22 36 45 98.8 249.4
ZNF587B 615.0 39.3 15.643 19q13.43a 43 40 427.6 32.2
SOSTDC1 111.7 8.6 12.957 7p21.1 43 45 176.5 108.4
LOC100287628* 1,381.3 107.7 12.820 16p13.2 9 7 80.2 56.8
Under-expressed genes
Hs.587427* 19.8 407.8 0.049 7p15.2 18 14 28.9 353.3
SPINK2 13.1 285.1 0.046 4q12 36 45 81.8 115.0
Hs.602709* 15.8 370.2 0.043 11q13.2a 9 7 33.1 256.9
RPS12 20.7 519.1 0.040 6q23.2 43 50 113.7 213.0
Hs.355689* 3.7 624.4 0.006 18q11.2a 9 7 47.3 168.4
b) DS AMKL vs. MK
Gene Value 'A' Value 'D' 'A'/'D' ratio Location Data points SD SD
'A' 'D' 'A' 'D'
Over-expressed genes
TMEM241 1,036.6 17.6 58.885 18q11.2 18 8 57.7 115.8
CMBL 592.4 11.7 50.759 5p15.2 27 8 142.0 30.1
IFI27 467.8 11.6 40.474 14q32 36 82 90.0 27.6
CSRNP1 640.6 16.8 38.023 3p22 9 8 41.3 138.3
PTGS2 2,205.0 59.2 37.276 1q25.2 q25.3 63 20 156.4 131.6
APOC2*b 431.7 11.7 37.044 19q13.2 54 28 81.4 41.6
SLITRK6b 465.5 13.3 35.057 13q31.1 27 10 113.0 95.6
Under-expressed genes
MAP3K10 5.4 2,352.3 0.002 19q13.2 36 19 47.4 135.1
DRD4 5.0 2,327.6 0.002 11p15.5 36 19 51.3 135.2
DLGAP3 4.8 2,297.9 0.002 1p35.3-p34.1 9 7 40.8 37.6
LBX1 2.7 1,358.5 0.002 10q24 36 19 46.4 152.6
TSPAN10* 7.9 4,674.7 0.002 17q25.3 9 8 55.0 46.0
c) Non-DS AMKL vs. MK
Gene Value 'B' Value 'D' 'B'/'D' ratio Location Data points SD SD
'B' 'D' 'B' 'D'
Over-expressed genes
TMEM241 2,754.1 17.6 156.443 18q11.2 14 8 89.9 115.8
CDYL2 1,613.5 13.1 122.994 16q23.2 7 8 128.9 69.8
MPV17L 1,857.8 24.4 76.280 16p13.11 7 8 119.5 65.0
ATP6V0D2 836.7 11.9 70.488 8q21.3a 21 10 169.4 82.9
CMBL 757.9 11.7 64.938 5p15.2 21 8 176.2 30.1
Under-expressed genes
ILDR1 13.7 4,333.8 0.003 3q13.33 14 9 98.4 63.3
HIST3H3 3.9 1,313.0 0.003 1q42 40 19 78.0 137.9
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Table 3 List of the five most over- or under-expressed genes (all significantly, with q < 0.05) (Continued)
TSPAN10* 12.1 4,674.7 0.003 17q25.3 7 8 88.1 46.0
MAP3K10 3.9 2,352.3 0.002 19q13.2 45 19 40.1 135.1
LBX1 2.0 1,358.5 0.001 10q24 45 19 85.7 152.6
Data refer to the following comparisons: a) DS AMKL (pool 'A') vs. non-DS AMKL (pool 'B'); b) DS AMKL (pool 'A') vs. MK (pool 'D'); c) non-DS AMKL (pool 'B') vs.
MK (pool 'D'). Value: mean gene expression value normalized across all the pool samples; data points: number of spots associated to an expression value for the
locus; SD: standard deviation for the expression value expressed as percentage of the mean. Full results available as additional material (see text). *The segment
window contains more than one gene, but the significance is assumed to be maintained because the expression value of this over- or under-expressed gene
prevails over the others.
aCytoband not available in Gene was derived from the UCSC Genome Browser [36].
bThis gene, exceeding the limit of five genes for each list, has been shown for its relevance in the Discussion, being recurrent in other comparisons.
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entially expressed gene between female (value=402.60)
and male (value=12.20) DS AMKL cells (ratio=33).
Transcriptome map comparison of DS AMKL or non-DS
AMKL vs. normal MK
Regional differential expression of pool 'A' (43 DS AMKL
samples) or pool 'B' (45 non-DS AMKL samples) versus
pool 'D' (19 normal MK cell samples, 411,381 data points)
(Table 1) was investigated. An 'A'/'D' ratio value was de-
terminable for 25,800 loci (Additional file 4). The main
results are shown in Figure 1.
For what DS AMKL samples are concerned, results
included 5 significantly differentially expressed segments
in DS AMKL cells, 3 over- and 2 under-expressed
(Table 2b). The highest expression ratio (20.81) be-
tween DS AMKL cells and normal MK was observed in
the segment at coordinates 3,500,001-4,000,000 on
chromosome 3, including the known gene LRRN1, en-
coding for a type I transmembrane protein. The second
segment with highest expression ratio (18.07) was lo-
cated on chromosome 1 (1q23) and contained FAM78B
(family with sequence similarity 78, member B). The
third segment was on chromosome 15 and included
NR2F2-AS1, a non-coding RNA. The first significantly
under-expressed segment (4q32.1) includes genes en-
coding for subunits of soluble guanylate cyclase
(GUCY1A3 and GUCY1B3), while the second spans the
cluster of MK specific genes located on chromosome 4
(4q12-q21).
At single gene level, a fold increase higher than 18 was
observed in all of the first 20 genes with the greatest ex-
pression ratios of DS AMKL vs. MK samples (Table 3b
and Additional file 4). In particular, a 59-fold increase
was observed for TMEM241, encoding a transmembrane
protein of unknown function. Among the genes with the
lowest 'A'/'D' expression ratio a 589.7-fold decrease was
observed for TSPAN10, encoding for tetraspanin 10.
At chromosomal level, the highest ratio was observed
for chr21 (1.75), the lowest (chr17), other values were in
the range from 1.68 (chrY) to a value of 1.23 for chr17.Regarding the non-DS AMKL samples, results ob-
tained by default analysis and derived from 'B'/'D' ex-
pression ratio for 25,819 loci included one significantly
over- and one significantly under-expressed segment
(Table 2c). The highest expression ratio (22.30) between
non-DS AMKL and normal MK was observed in the
same segment on chr15, significantly over-expressed also
in the DS AMKL transcriptome map. This segment was
the only significantly over-expressed one in this com-
parison. Similarly, the only significantly under-expressed
segment includes the cluster of MK specific genes on
chromosome 4 also found to be under-expressed in DS
AMKL samples (Table 2b).
At single gene level, a fold increase higher than 31 was
observed in all of the first 20 genes with the greatest expres-
sion ratios of non-DS AMKL vs. MK samples (Table 3c and
Additional file 5). In particular, a 156-fold increase was ob-
served for TMEM241. Overall, there was a remarkable over-
lap between the most over- (TMEM241, CMBL, ZNF445,
SPRR4) and under-expressed (PF4V1, FLJ22184, FSIP2,
PPP1R3B, HIST3H3, PIF1, SPSB4, ILDR1, MAP3K10,
DRD4, LBX1, TSPAN10) genes in DS and in non-DS
AMKL samples (Additional files 4 and 5).
At chromosomal level, looking at the median 'B'/'D' ex-
pression ratio for the genes located in the same chromo-
some, the highest ratio was observed for chr21 (1.77) and
chrY (1.73), followed by chr13 (1.71) and chr10 (1.59);
other values were in the range from 1.58 (chr20), to a
value of 1.24 (chrX).Transcriptome map comparison of DS AMKL or non
DS AMKL vs. normal CB MK
Regional differential expression of pool 'A' (43 DS AMKL
samples) or pool 'B' (45 non-DS AMKL samples) versus
pool 'E' (8 normal cord blood (CB)-derived MK cell sam-
ples, 191,798 data points) (Table 1) was investigated. The
main results are shown in Figure 2.
For what DS AMKL samples are concerned, results
derived from 'A'/'E' expression ratio for 25,540 loci
(Additional file 6) included 1 significantly over- and 3
Figure 2 Main results of DS AMKL vs. CB MK and non-DS AMKL vs. CB MK comparisons. For each comparison the number of loci analyzed,
the most over- or under-expressed segments and single genes, and the highest and lowest median expression ratios for all the genes located in
the same chromosome are indicated.
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A remarkable expression ratio (80.36) between DS
AMKL cells and normal CB MK was observed for a seg-
ment on chromosome 3 (3q22.1), including collagen-
encoding COL6A5 and COL6A6 known loci. The three
significantly under-expressed segments included the re-
gion on chromosome 4 (4q12-q21) with PF4, PPBP and
CXCL3 loci implied in MK differentiation.
At single gene level, a fold increase higher than 15.7
was observed in all of the first 20 genes with the greatest
expression ratios of DS AMKL cells vs. CB MK (Table 5a
and Additional file 6). In particular, a 45-fold increase was
observed for the tyrosine phosphatase receptor gene
(PTPRO), known to be involved in megakaryocytopoiesis.
At chromosomal level, the highest ratio was ob-
served for chr21 (2.08), followed by chrY (1.89); other
values were in the range from 1.84 (chr22) to 1.37
(chrX).
Regarding the non-DS AMKL samples, results derived
from 'B'/'E' expression ratio (for 25,546 loci) included 2
significantly over- and 1 under-expressed segments innon-DS AMKL (Table 4b). A remarkable expression ratio
between non-DS AMKL and normal CB MK (116.13) was
observed in the same segment on chromosome 3 (3q22.1),
including collagen-encoding COL6A5 and COL6A6 known
loci that was observed in DS AMKL samples. The second
segment was specific of non-DS AMKL samples and in-
cluded the two olfactive receptor genes OR10A5 and
OR10A4. The only significantly under-expressed segment
included the region on chromosome 4 (4q12-q21) highly
enriched in MK-specific loci (PF4, PPBP, CXCL5 and
CXCL3) as in the case of DS AMKL samples, and was ex-
tended to PF4V1 locus.
At single gene level, a fold increase higher than 14.7
was observed in all of the first 20 genes with the greatest
expression ratios of non-DS AMKL vs. CB MK samples
(Table 5b and Additional file 7). In particular, a 33.8-fold
increase was observed for PTPRO, encoding a tyrosine
phosphatase receptor. Overall, there was some overlap-
ping between the most over- and under-expressed genes
in DS and in non-DS AMKL samples (Additional file 6
and Additional file 7).
Table 4 Genomic segments significantly over- or under-expressed
a) DS AMKL vs. normal CB MK
Chr and locationa Segment startb Segment endb 'A'/'E' ratio q-value Genes in the segmentc
Over-expressed segments
chr3 3q22.1 130,000,001 130,500,000 80.36 0.00015 COL6A5+ COL6A6+ Hs.596709+ Hs.596805+ PIK3R4-
Under-expressed segments
chr7 7q11.23 77,000,001 77,500,000 0.48 0.00117 GSAP- PTPN12- LOC101059910- RSBN1L-AS1- RSBN1L-
Hs.594486- Hs.720279- TMEM60- PHTF2-
chr4 4q12-q21 74,750,001 75,250,000 0.37 0.00119 PF4- PPBP- CXCL5- CXCL3- CXCL2- MTHFD2L- Hs.662627-
EREG-
chr4 4q32.1 156,250,001 156,750,000 0.12 0.00000 MAP9- GUCY1A3- Hs.612374- GUCY1B3-
b) Non-DS AMKL vs. normal CB MK
Chr and location Segment start Segment end 'B'/'E' ratio q-value Genes in the segment
Over-expressed segments
chr3 3q22.1 130,000,001 130,500,000 116.13 0.00030 COL6A5+ COL6A6+ Hs.596709+ Hs.596805+ PIK3R4-
chr11 11p15 6,750,001 7,250,000 50.98 0.00117 OR6A2+ OR10A5+ OR10A4+ ZNF215- ZNF214- Hs.445849+
NLRP14+ RBMXL2- LOC100506238+
Under-expressed segments
chr4 4q12-q21 74,750,001 75,250,000 0.42 0.00003 PF4- PPBP- CXCL5- CXCL3- CXCL2- MTHFD2L- Hs.662627-
EREG-
Data refer to the following comparisons: a) DS AMKL (pool 'A') vs. normal CB MK (pool 'E'); b) non-DS AMKL (pool 'B') vs. normal CB MK (pool 'E'). Analysis was
performed using default parameters (see Methods section). Segments are sorted by increasing 'A'/'E' ratio in a), 'B'/'E' ratio in b). In the "Map" mode, TRAM displays
UniGene EST clusters (with the prefix "Hs." in the case of H. sapiens) only if they have an expression value. Some segments are not shown for simplicity because
they are over-lapping with those highlighted in one of the listed regions. The complete results for this model are available as on line additional material.
aChr: chromosome. The segment location cytoband was derived from that of the first mapped gene within the segment.
bSegment Start/End: chromosomal coordinates for each segment.
cBold and '+': over-expressed gene; bold and '-': under-expressed gene; '+' or '-': gene expression value higher or lower than the median value, respectively.
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pression ratio for the genes located in the same chromo-
some, the highest ratio was observed for chrY (2.51),
followed by chr21 (2.19); other values were in the range
from 2.03 (chr20) to 1.46 (chrX).
Transcriptome map comparison of DS AMKL vs. TMD
Regional differential expression of pool 'A' (43 DS AMKL
samples) versus pool 'C' (20 TMD samples, 398,162 data
points) (Table 1) was investigated. The main results are
shown in Figure 3.
Results obtained by default analysis and derived from
'A'/'C' expression ratio for 25,955 loci (Additional file 8)
included 2 significantly over-expressed segments in DS
AMKL (Table 6a). The highest expression ratio (2.20) be-
tween DS AMKL and TMD was observed in a segment on
chromosome 2 (2q31.3), including the known gene ITGA4,
encoding an alpha 4 chain of integrin protein and CERKL,
a gene responsible for retinitis pigmentosa and involved in
the protection of cells from apoptosis induced by oxidative
stress [47]. The second segment with the highest expres-
sion ratio (1.40) was located on chromosome 8 (8q21.3)
and contained the NECAB1 and OTUD6B genes, encoding
for neuronal Ca(2+)-binding protein and the deubiquiti-
nating enzyme, respectively.At single gene level, a fold increase ranged from 15.5 to
3.5 for the first 20 genes with the greatest expression ratios
of DS AMKL vs. TMD samples (Table 7a and Additional
file 8). The highest fold increases were observed for the
ZNF587B (15.5) and IFI27 (13.4) genes, encoding for a
zinc finger protein and the interferon alpha-inducible pro-
tein 27, respectively. The lowest 'A'/'C' expression ratios
were observed for KIAA2022 (10-fold decrease) and
SLFNL1 (5-fold decrease) genes.
At chromosomal level, the highest ratio was observed
for chr14 (0.87, followed by 0.86 for chr5, chr21, chr8,
chr12 and chr16), the lowest for chrY (0.74).Transcriptome map comparison of TMD vs. normal MK or
CB MK cells
Regional differential expression of pool 'C' (20 TMD
samples) versus pool 'D' (19 MK samples) or 'E' (8 CB
MK samples) (Table 1) was investigated. The main re-
sults are shown in Figure 3.
For what MK samples are concerned, results obtained
by default analysis and derived from 'C'/'D' expression
ratios for 25,800 loci (Additional file 9) included 2
significantly over-expressed segments in TMD cells
(Table 6b).
Table 5 List of the five most over- or under-expressed genes (all significantly, with q <0.05)
a) DS AMKL vs. normal CB MK
Gene Value 'A' Value 'E' Ratio 'A'/'E' Location Data points SD SD
'A' 'E' 'A' 'E'
Over-expressed genes
PTPRO 679.7 15.1 45.063 12p13-p12 81 9 133.0 60.8
APOC2a 431.7 9.9 43.477 19q13.2 54 10 81.4 43.4
IFI27 467.8 11.5 40.742 14q32 36 8 90.0 57.1
HDC 1,119.4 34.2 32.716 15q21-q22 36 8 98.8 168.1
VIPR2ab 346.2 13.5 25.582 7q36.3 115 23 334.8 49.3
Under-expressed genes
CDKL1 4.6 174.3 0.027 14q21.3 45 9 65.3 99.0
ASAP2 19.1 734.1 0.026 2p24 36 8 95.4 67.3
GNG11 18.9 1,042.3 0.018 7q21 36 8 119.7 81.2
RPS12 20.7 1,157.2 0.018 6q23.2 43 15 113.7 112.4
OLFM4 8.9 499.3 0.018 13q14.3 36 7 83.9 121.5
b) Non-DS AMKL vs. normal CB MK
Gene Value 'B' Value 'E' Ratio 'B'/'E' Location Data points SD SD
'B' 'E' 'B' 'E'
Over-expressed genes
PTPROb 510.3 15.1 33.831 12p13-p12 97 9 137.8 60.8
CES3b 287.4 12.2 23.511 16q22.1 47 9 335.8 73.8
SCD5ab 544.7 27.2 19.992 4q21.22 61 18 290.3 73.9
TOP3Bab 150.2 7.5 19.922 22q11.22 60 14 431.8 19.7
MT1Eab 237.1 11.9 19.899 16q13 45 8 92.5 27.3
Under-expressed genes
Hs.23729a 2.3 85.1 0.027 1p13.2c 40 8 121.0 89.5
PDE6C 2.2 88.2 0.025 10q24 45 8 112.9 105.9
SPTLC3 4.8 203.7 0.023 20p12.1 47 9 86.5 110.7
SPATA1 7.0 356.2 0.020 1p22.3 40 7 127.4 77.9
OLFM4 9.7 499.3 0.020 13q14.3 45 7 105.1 121.5
Data refer to the following comparisons: a) DS AMKL (pool 'A') vs. normal CB MK (pool 'E'); b) non-DS AMKL (pool 'B') vs. normal CB MK (pool 'E'). Value: mean
gene expression value normalized across all the pool samples; data points: number of spots associated to an expression value for the locus; 'SD': standard
deviation for the expression value expressed as percentage of the mean. Full results available as additional material (see text).
aThe segment window contains more than one gene, but the significance is assumed to be maintained because the expression value of this over- or under-expressed
gene prevails over the others.
bAccording to the criteria detailed in Methods section, this gene is one of the five most over-expressed ones, but the value is not statistically significant due to
the presence of a lot of loci associated with less than 5 data points in the CB MK integrated dataset.
cCytoband not available in Gene was derived from the UCSC Genome Browser [36].
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normal MK was observed in a segment on chromosome 3
including the known gene LRRN1, already observed as over-
expressed in comparison of DS AMKL vs. normal MK
(Table 2b). The second segment with the highest expression
ratio (19.9) was located on chromosome 15, and contained
the locus NR2F2-AS1, encoding for an antisense mRNA,
already observed as over-expressed in comparison of DS
AMKL and non-DS AMKL vs. normal MK (Table 2b and 2c).At single gene level, the fold increase was higher
than 16.5 for the first 20 genes with the greatest ex-
pression ratios (Table 7b and Additional file 9), with
the highest fold increases for TMEM241 (126.4) and
the cysteine hydrolase gene (CMBL) (91.1). The low-
est 'C'/'D' expression ratios were observed for a mem-
ber of the serine/threonine kinase family (MAP3K10)
and the homeobox gene (LBX1) (both with 333-fold
decrease).
Figure 3 Main results of DS AMKL vs. TMD, TMD vs. MK, TMD vs. CB MK comparisons. For each comparison the number of loci analyzed,
the most over- or under-expressed segments and single genes, and the highest and lowest median expression ratios for all the genes located in
the same chromosome are indicated.
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for chrY (2.1) and chr21 (1.93), followed by chr13 (1.71),
the lowest for chrX (1.33).
As far as the comparison of TMD with CB MK sam-
ples is concerned, results derived from the 'C'/'E' expres-
sion ratio for 25,540 loci (Additional file 10) included
only 1 significantly over-expressed segment in TMD
cells (Table 6c). The segment with a significant high ex-
pression ratio (76.0) between TMD and normal CB MK
cells was on chromosome 3 (3q22.1), including the
known genes COL6A5 and COL6A6 and already ob-
served as over-expressed in DS as well in non-DS AMKL
samples in comparison with CB MK samples.
At single gene level, a fold increase ranged from 44.9
to 15.1 for the first 20 genes with the greatest expression
ratios (Table 7c and Additional file 10). The highest foldincreases were observed for CGA (44.9), encoding for
the alpha chain of the glycoprotein hormones and
PTPRO (34.7), as already observed in non-DS AMKL vs.
CB MK comparison. The lowest 'C'/'E' expression ratio
was observed for OLFM4 (50-fold decrease), encoding
olfactomedin 4, an antiapoptotic factor that promotes
tumor growth.
At chromosomal level, the highest ratio was observed
for chr21 (2.40), followed by chrY (2.37) and chr20
(2.13), the lowest for chrX (1.53).
Comparison with previously published data
As a result of the analysis above described, a reference in-
tegrated map for the expression of about 26,000 mapped
sequences (~75% known genes and ~25% expression
Table 6 Genomic segments significantly over- or under-expressed
a) DS AMKL vs. TMD
Chra and location Segment startb Segment endb 'A'/'C' ratio q-value Genes in the segmentc
Over-expressed segments
chr2 2q31.3 182,000,001 182,500,000 2.20 0.00045 ITGA4+ Hs.660611- Hs.658786+ CERKL+ Hs.72981+
chr8 8q21.3 91,750,001 92,250,000 1.40 0.00051 NECAB1+ Hs.743640+ LOC100127983+ TMEM55A+
LOC100506365- OTUD6B+ LRRC69+
b) TMD vs. normal MK
Chr and location Segment start Segment end 'C'/'D' ratio q-value Genes in the segment
Over-expressed segments
chr3 3p26.2 3,500,001 4,000,000 28.00 0.00006 Hs.241414+d Hs.587205+ LRRN1+ Hs.128128+
chr15 15q26.2 96,750,001 97,250,000 19.86 0.00000 Hs.677040+d Hs.661950+d NR2F2-AS1+ NR2F2- Hs.592015+
c) TMD vs. normal CB MK
Chr and location Segment start Segment end 'C'/'E' ratio q-value Genes in the segment
chr3 3q22.1 130,000,001 130,500,000 75.97 0.00015 COL6A5+ COL6A6+ Hs.596709+ Hs.596805+ PIK3R4-
Data refer to the following comparisons: a) DS AMKL (pool 'A') vs. TMD (pool 'C'); b) TMD (pool 'C') vs. normal MK (pool 'D'); c) TMD (pool 'C') vs. normal CB MK
(pool 'E'). Analysis was performed using default parameters (see Methods section). Segments are sorted by increasing 'A'/'C' ratio in a), 'C'/'D' ratio in b) and 'C'/'E'
ratio in c). In the "Map" mode, TRAM displays UniGene EST clusters (with the prefix "Hs." in the case of H. sapiens) only if they have an expression value. Some
segments are not shown for simplicity because they are over-lapping with those highlighted in one of the listed regions. The complete results for this model are
available as additional material on line.
aChr: chromosome. The segment location cytoband was derived from that of the first mapped gene within the segment.
bSegment Start/End: chromosomal coordinates for each segment.
cBold and '+': over-expressed gene; bold and '-': under-expressed gene; '+' or '-': gene expression value higher or lower than the median value, respectively.
dThis UniGene cluster contains EST with at least one Alu sequence, according to Repeat Masker [46]. For this reason, it can not be excluded that its over-expression is
related to non-specific hybridization by Alu-containg probes.
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types (DS AMKL cells, non-DS AMKL cells, TMD cells,
MK and CB MK). This gave us the opportunity to com-
pare our data with the expression values of specific known
genes from previously published works about the consid-
ered cell types.
Following analysis of the main literature about AMKL,
we selected 38 genes of interest and have tabulated their
expression values desumed from our 8 differential maps,
comparing these values to the ones previously described
in different experimental settings (Table 8).
The wide agreement of expression ratio values for spe-
cific genes between our data, generated by systematic
meta-analysis of hundred of thousands of gene expression
values from any gene expression profile available, and the
data obtained by different marker-specific methods in pub-
lished quantitative studies, is relevant for the validation of
our maps that may so be used for exploring any other ex-
pression ratio in the considered biological conditions.
Discussion
We have presented here a comprehensive analysis of
transcriptome in human DS AMKL cells. Integration of
data from different sources, including data obtained
from different Authors using a variety of platforms, was
made possible by a recent approach described by us for
creation and analysis of transcriptome maps [25]. While
most approaches are aimed to separate gene expression
profiles related to the same biological source insubclasses, the TRAM tool provides means to integrate
and summarize a pool of samples of the same biological
origin leading to a global picture of gene expression for
that condition. Moreover, TRAM identifies critical gen-
omic regions and genes with significant differential ex-
pressions between two biological conditions.
Several Authors have determined gene expression pro-
files for DS or non-DS AMKL samples or have explicitly
compared these two leukemic conditions. However, due
to the rarity of the M7 subtype of leukemia and the need
to limit the analysis to pediatric age because DS AMKL
occurs almost exclusively in children, these studies were
typically limited to small group of samples. In addition,
most platforms used in the microarray studies are af-
fected by omissions or errors in mapping a certain per-
centage of probes to specific loci in the genome. In our
analysis, the use of a new version of the TRAM software
(TRAM 1.1) allowed us to map thousands of previously
uncharacterized microarray probes and to avoid the er-
rors in probe assignment to human loci often present in
the data supplied by the manufacturer along with the
platforms.
Our data are derived from systematic integration of data
from multiple sources at locus level (up-to-date rigorous
assignment of each microarray probe to a specific human
locus/transcript/EST cluster), map level (up-to-date fine
mapping of each transcript on the genome map) and ex-
pression value level (assignment of a reference value to
each locus in each cell type following an intra- and inter-
Table 7 List of the five genes most over- or under-expressed (all significantly, with q <0.05)
a) DS AMKL vs. TMD
Gene Value 'A' Value 'C' Ratio 'A'/'C' Location Data points SD SD
'A' 'C' 'A' 'C'
Over-expressed genes
ZNF587B 615.0 39.7 15.498 19q13.43c 43 20 427.6 20.9
IFI27 467.8 34.8 13.431 14q32 36 11 90.0 91.4
SLITRK6 465.5 38.7 12.036 13q31.1 27 9 113.0 84.5
BST2a 117.6 14.8 7.967 19p13.1 36 11 260.0 98.8
ZNF521 143.0 19.6 7.309 18q11.2 18 6 113.5 58.6
Under-expressed genes
ALS2CR12 4.2 15.8 0.268 2q33.1 18 6 80.3 103.2
GBP5 11.6 43.8 0.266 1p22.2 18 6 75.7 110.6
GHRH 14.7 67.1 0.219 20q11.2 43 20 97.7 257.0
SLFNL1a 18.9 92.9 0.203 1p34.2 18 6 90.3 122.1
KIAA2022 24.3 297.9 0.081 Xq13.3 27 9 52.2 260.9
b) TMD vs. normal MK
Gene Value 'C' Value 'D' Ratio 'C'/'D' Location Data points SD SD
'C' 'D' 'C' 'D'
Over-expressed genes
TMEM241 2,224.4 17.6 126.356 18q11.2 6 8 57.1 115.8
CMBL 1,063.5 11.7 91.126 5p15.2 9 8 168.8 30.1
PTGS2 2,256.4 59.2 38.145 1q25.2-q25.3 20 20 147.6 131.6
CGA 360.6 10.0 36.238 6q12-q21 14 19 159.7 27.3
TMEFF2 755.1 22.5 33.605 2q32.3 9 9 190.3 44.3
Under-expressed genes
ILDR1 18.3 4,333.8 0.004 3q13.33 6 9 58.9 63.3
DRD4 9.3 2,327.6 0.004 11p15.5 11 19 52.3 135.2
HIST3H3 5.2 1,313.0 0.004 1q42 11 19 36.2 137.9
LBX1 4.3 1,358.5 0.003 10q24 11 19 26.6 152.6
MAP3K10 7.4 2,352.3 0.003 19q13.2 11 19 28.8 135.1
c) TMD vs. normal CB MK
Gene Value 'C' Value 'E' Ratio 'C'/'E' Location Data points SD SD
'C' 'E' 'C' 'E'
Over-expressed genes
CGA 360.6 8.0 44.869 6q12-q21 14 8 159.7 39.9
PTPROb 523.1 15.1 34.680 12p13-p12 25 9 116.8 60.8
CLCA1b 319.2 9.9 32.380 1p22.3 20 8 116.7 17.5
APOC2ab 301.6 9.9 30.372 19q13.2 17 10 66.6 43.4
HDCab 918.0 34.2 26.830 15q21-q22 11 8 59.9 168.1
Under-expressed genes
CDKL1 5.9 174.3 0.034 14q21.3 14 9 82.0 99.0
GNG11 34.3 1,042.3 0.033 7q21 11 8 80.1 81.2
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Table 7 List of the five genes most over- or under-expressed (all significantly, with q <0.05) (Continued)
RHOBTB1 7.7 241.3 0.032 10q21.2 20 8 49.7 97.4
RPS12 34.6 1,157.2 0.030 6q23.2 20 15 77.4 112.4
OLFM4 10.0 499.3 0.020 13q14.3 11 7 56.0 121.5
Data refer to the following comparisons: a) DS AMKL (pool 'A') vs. TMD (pool 'C'); b) TMD (pool 'C') vs. normal MK (pool 'D'); c) TMD (pool 'C') vs. normal CB MK
(pool 'E'). Value: mean gene expression value normalized across all the pool samples; data points: number of spots associated to an expression value for the locus;
'SD': standard deviation for the expression value expressed as percentage of the mean. Full results available as additional material (see text).
aThe segment window contains more than one gene, but the significance is assumed to be maintained because the expression value of this over- or under-expressed
gene prevails over the others.
bAccording to the criteria detailed in Methods section, this gene is one of the five most over-expressed ones, but the value is not statistically significant due to
the presence of a lot of loci associated with less than 5 data points in the CB MK integrated dataset.
cCytoband not available in Gene was derived from the UCSC Genome Browser [36].
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ric and non-parametric calculations). The combination of
many gene expression profile datasets from different
sources poses the problem of the batch effect, i.e. the sys-
tematic differences between batches (groups) of samples
in microarray experiments due to purely technical reasons.
However, the intrinsic resistance of the TRAM approach
to the batch effect has been discussed previously [25], and
it is indirectly confirmed by the clear biological meaning
of the differential expression highlighted by the tool when
comparison with previous direct key experimental know-
ledge is possible in several different types of tissues and or-
gans [25,34,54].
A systematic comparison of AMKL originated from
trisomy 21 cells versus non-trisomy 21 cells should high-
light specific mechanisms [55] related to the presence of
an extra copy of chr21 in DS children developing
AMKL. Moreover, we presented a comparison with nor-
mal MK cells that has never been performed in other
analyses about AMKL. Our global quantitative models
of the transcriptome in the AMKL cells could also be
useful to test hypotheses for correlations between any
parameter associated to the condition (e.g., specific mu-
tations or phenotype aspects) and specific changes in
gene expression.
Our results, obtained in an integrated and open setting
without any a priori assumption, show several previously
unidentified aspects regarding specificity of AMKL origi-
nated by trisomy 21 cells.
First, there are only a few genomic regions significantly
over- or under-expressed when comparing DS versus non-
DS AMKL samples. This finding suggests that transcrip-
tome maps of these two conditions are similar while on
the other hand allows to focus to a small set of regions
that appears to be critical in order to differentiate these
disease conditions. Relevant differences regarding genes
were reported in Table 2a (genomic segments) and Table 3a
(single genes), with potential implications for the identifi-
cation of diagnostic or therapeutic targets. There are three
main regions over-expressed in DS AMKL vs. non-DS
AMKL (Table 2a). The first one (15q21.2) contains HDCgene, whose mRNA is translated in the enzyme converting
L-histidine to histamine produced by only a few cell types
[56]; HDC mRNA increase has been shown to be associ-
ated to basophilic rather than to MK differentiation of
pluripotent hematopoietic cells [57]. These observations
led to the discovery of a skewing toward a potential baso-
philic differentiation for DS AMKL not highlighted in the
original works from which the data were derived. Support-
ing this hypothesis, FCER1A mRNA, encoding the alpha
subunit of the high-affinity IgE receptor, the initiator of
the allergic response and strongly typical of basophilic dif-
ferentiation, is 6.3 times over-expressed (the 8th most
over-expressed known gene) in DS vs. non-DS AMKL, re-
inforcing the notion that in DS AMKL but not in non-DS
AMKL the leukemic dedifferentiation involved the pos-
sibility of redirection toward basophilic differentiation.
Remarkably, in [58] is demonstrated by an electron mi-
croscopy analysis that AMKL blast cells from children
with DS may contain basophil-like granules which were al-
most totally absent in blasts from children with non-DS
AMKL or adults with AMKL, so that our data allow to
the visualization of the molecular correlation at the level
of the whole transcriptome of a morphological feature ob-
served more than 20 years ago. Two other genomic re-
gions are over-expressed in DS vs. non-DS AMKL blasts.
The first is the region of glycophorins genes (GYPE, GYPA,
GYPB) on chr4, erythroid surface markers [59]: this rein-
forces the concept of a disturbance of multilineage mye-
loid hematopoiesis in DS AMKL and has been observed
by flow cytometry in the non-neoplastic hematopoiesis it-
self in trisomy 21 [60]. The other is the region of apolipo-
proteins genes (APOC1, APOC2, APOE) on chr19 that has
been described as a signature of progression from TMD to
DS AMKL in a gene expression profile ([20], it was not
possible to include this in our analysis), further underlining
its specificity for DS vs. non-DS MK blast cells.
When grouping expression values by chromosome, the
chromosome with the greatest global RNA output was
chr21 in both TMD and DS AMKL vs. normal CB MK;
we observed the same result in both DS and non-DS
AMKL vs. normal MK comparisons. These data suggest
Table 8 Comparison with previously published data
Gene Location References 'A'/'B' 'A'/'D' 'B'/'D' 'A'/'E' 'B'/'E' 'A'/'C' 'C'/'D' 'C'/'E'
MK markers
BST2 19p13.11 [23] 0.53 5.36 10.07 7.21 13.56 7.97 0.67 0.91
GATA1 Xp11.23 [13,22,48] 3.39 1.45 0.43 1.97 0.58 1.19 1.22 1.66
GP1BA 17p13.2 [43] 0.46 0.07 0.14 0.25 0.53 0.81 0.08 0.30
HBG1 11p15.5 [22] 2.36 1.40 0.59 1.07 0.45 0.78 1.79 1.37
HBG2 11p15.5 [22] 2.47 1.31 0.53 1.06 0.43 0.71 1.84 1.48
ITGA2B 17q21.32 [23] 0.82 0.63 0.77 1.52 1.84 1.05 0.60 1.44
ITGB3 17q21.32 [23] 0.75 0.08 0.10 0.10 0.13 0.65 0.12 0.15
PF4 4q12-q21 [25] 0.90 0.06 0.06 0.11 0.12 0.44 0.13 0.25
PPBP 4q12-q13 [25] 1.45 0.10 0.07 0.13 0.09 0.28 0.34 0.44
TAL1 1p32 [23] 0.85 0.19 0.22 0.16 0.19 1.05 0.18 0.16
Chr21 genes
ADAMTS1 21q21.2 [49] 6.19 7.02 1.14 7.14 1.15 1.82 3.85 3.91
BACH1 21q22.11 [22] 1.86 1.44 0.77 1.04 0.56 1.55 0.93 0.67
DYRK1A 21q22.13 [50] 1.61 0.87 0.54 0.63 0.39 1.14 0.77 0.55
ERG 21q22.3 [18,22] 0.68 3.47 5.12 3.10 4.57 1.42 2.44 2.18
ETS2 21q22.2 [18,22] 0.93 1.11 1.20 1.39 1.49 0.73 1.52 1.90
GABPA 21q21.3 [18,22] 1.39 2.45 1.76 1.52 1.10 1.55 1.58 0.98
RUNX1 21q22.3 [18,22] 0.71 1.08 1.51 0.84 1.18 1.06 1.01 0.80
SOD1 21q22.11 [51] 1.88 1.52 0.81 2.78 1.48 1.52 1.00 1.84
SON 21q22.11 [22] 1.28 1.39 1.08 1.03 0.80 1.44 0.96 0.71
Other genes
APOC1 19q13.2 [20,22,23] 4.37 10.04 2.30 16.26 3.72 1.79 5.63 9.11
APOC2 19q13.2 [22] 4.36 37.04 8.49 43.48 9.96 1.43 25.88 30.37
APOE 19q13.2 [22,23] 2.18 3.57 1.64 3.24 1.48 1.56 2.30 2.08
CDA 1p36.2-p35 [23] 0.39 0.40 1.03 0.88 2.24 0.88 0.46 1.00
DICER1 14q32.13 [18] 0.80 0.41 0.51 0.27 0.34 0.99 0.41 0.27
FCER1A 1q23 [22,23] 6.32 4.28 0.68 8.86 1.40 1.32 3.25 6.72
GYPA 4q31.21 [23] 3.40 1.56 0.46 0.89 0.26 1.19 1.31 0.75
GYPB 4q31.21 [23] 2.81 1.28 0.46 0.89 0.31 1.27 1.01 0.70
GYPE 4q31.1 [23] 2.07 1.63 0.79 1.71 0.82 1.72 0.95 0.99
HDC 15q21-q22 [22,23] 17.10 9.95 0.58 32.72 1.91 1.22 8.16 26.83
IGF1R 15q26.3 [17] 0.76 1.18 1.55 0.94 1.24 1.21 0.98 0.78
ITGAL 16p11.2 [52] 0.79 0.21 0.26 0.09 0.11 1.02 0.20 0.09
KIT 4q11-q12 [22] 1.66 3.34 2.01 3.08 1.85 1.22 2.74 2.53
MPL 1p34 [53] 1.11 0.31 0.28 0.22 0.20 1.23 0.25 0.18
MTOR 1p36.22 [17] 0.87 1.57 1.82 1.94 2.24 0.89 1.76 2.17
MYCN 2p24.3 [21] 0.35 1.00 2.87 0.77 2.19 0.34 2.99 2.28
PRAME 22q11.22 [21] 1.60 11.59 7.24 15.61 9.76 4.18 2.77 3.73
SMOX 20p13 [23] 1.37 0.76 0.55 1.02 0.75 0.79 0.96 1.30
ST18 8q11.23 [18] 0.90 0.74 0.82 0.74 0.82 0.78 0.96 0.95
Expression values of genes known for their role in MK differentiation and DS or non-DS AMKL development in each of the eight comparisons: DS AMKL (pool 'A') vs. non-DS
AMKL (pool 'B'); DS AMKL (pool 'A') vs. normal MK (pool 'D'); non-DS AMKL (pool 'B') vs. normal MK (pool 'D'); DS AMKL (pool 'A') vs. normal CB MK (pool 'E') cells; non-DS
AMKL (pool 'B') vs. normal CB MK (pool 'E'); DS AMKL (pool 'A') vs. TMD (pool 'C'); TMD (pool 'C') vs. normal MK (pool 'D'); TMD (pool 'C') vs. normal CB MK (pool 'E'). Data
extracted from the full tables showing expression values and their ratio for about 17-26,000 loci for each comparison. In bold: expression ratio values are consistent with data
available in the literature (see references indicated). The other values are reported for completeness. Descriptions of the gene symbols are given in Additional file 2.
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AMKL development. In particular, ADAMTS1, encoding
a protease known to inhibit angiogenesis [61] is the most
over-expressed chr21 gene in DS vs. non-DS AMKL
comparison. It is interesting to notice that this gene has
been correlated to pediatric leukemias (ALL and DS
AML) [49,62] but its exact role in leukemogenesis is still
to be discovered. Our quantitative approach summariz-
ing all values for each locus may clearly highlight mean
expression ratio near to 1.5:1 for several chr21 genes
when comparing DS AMKL vs. non-DS AMKL. This ob-
servation is consistent with the presence of an additional
copy of the considered genes in trisomic cells. For ex-
ample, GABPA expression presents a ratio close to 1.5:1
expected in trisomy of chr21, as well as other chr21
genes (DYRK1A, SON, BACH1) (Table 8). Even relatively
small but significant differences (around 1.5-fold) in ex-
pression of numerous genes likely produce an aggregate
effect, as observed in [63], where the same genes seem
to be candidates to explain the impact of trisomy 21 in
hematopoiesis abnormalities. For this reason it could be
interesting to start from significant and robust meta-
analysis data to plan functional approaches in the future.
Moreover, our data are consistent with the previous obser-
vation that RUNX1, ERG and ETS2 oncogenes, although
located on chr21, are not over-expressed in DS vs. non-DS
AMKL [18,22]. It has also been recently demonstrated
that they are not located on a chr21 duplicated minimal
region in two cases of AML of M0 subtype (FAB classifi-
cation) [64]. As regard oncogenes, if chr21 oncogenes
cited above appear not to be over-expressed in DS AMKL,
TRIB1 (chr8) may be a novel important oncogene for DS
AMKL and its mutation is an earlier genetic event in
leukemogenesis [65]. In particular, it has been shown that
a mutation of TRIB1 [65], a myeloid oncogene whose pro-
tein product is able to enhance ERK phosphorylation and
to promote degradation of C/EBP family transcription
factors, is a gain-of-function mutation remaining in leu-
kocytes of the remission stage in which GATA1 muta-
tion disappeared. Our results show a mean value of 1.40
for the human TRIB1 expression ratio between DS and
non-DS AMKL samples, with a higher over-expression
observed when comparing leukemic samples to normal
MK (ratio 3.15 for DS AMKL and 2.26 for non-DS
AMKL).
Although the expression of chr21 genes as a whole, or
of some individual chr21 genes, may be coherent with
the 3:2 gene expression ratio model in the comparison
between trisomic and euploid cells, we note that discrep-
ancies from this ideal model seen in our data for some
of the comparisons we have made (Figures 1, 2 and 3)
may be ascribed to the complexity of gene regulation in
the aneuploid state [66,67], to individual variability [68]
as well as to the general dysregulation typical of theneoplastic state for which specific cell types we analyze
is concerned.
Additional biologically relevant findings came from
comparison of each type of megakaryoblastic leukemic
condition with normal MK cells. Due to the role of the
microenvironment in the hemopoiesis, including hemo-
poiesis in DS [69], it is expected that DS MK would
present growth alterations due to trisomy 21 in both
hemopoietic and microenvironment cells. From this point
of view, DS MK cells would be the ideal control for the
progression of a trisomic cell toward TMD and AMKL,
however no gene expression profile dataset was available
for this cell type. We propose here a biological model of
the transcriptome depicting progressive changes from nor-
mal MK to TMD and then to DS AMKL, able to under-
line both shared and unique transcriptome map patterns
for DS and non-DS variants of AMKL (Figure 4).
Noteworthy, the genomic segment on chr4 known to
contain a cluster of genes highly specific for MK differ-
entiation [25,70], was the highest significantly under-
expressed segment in both DS and non-DS AMKL in
comparison with normal MK. In particular, the more
strongly under-expressed region 4q12-q21 contains a
cluster of genes, including PF4 (encoding for the platelet
factor 4, a main component of platelet alpha granules)
[71-73], and PPBP (encoding for beta-thromboglobulin)
[70], that are the most up-regulated transcripts in the
megakaryocytic differentiation from CD34+ hematopoietic
progenitors [25]. This finding highlights a common final
outcome of the block of MK cells differentiation in both
DS and non-DS AMKL. It should be underlined that this
result came from systematic ab initio analysis of more
than 12,000 segments on the human genome including
about 26,000 mapped loci, thus highlighting that this re-
gion critical for the MK differentiation is actually the more
repressed in absolute when comparing transcriptome
maps of AMKL (DS or non-DS) and normal MK cells.
In addition, the most under-expressed gene in TMD
blasts when compared to normal MK cells is MAP3K10,
encoding an activity of mitogen-activated protein kinase
kinase kinase (MAPKKK). It is known that the mitogen-
activated protein kinase (MAPK) pathway is involved in
and is sufficient for megakaryocytic differentiation [74,75].
MAPK activity is present in several tens of human pro-
teins, and we have identified the member MAP3K10 as
the critically repressed gene in the block of MK differenti-
ation in the development of leukemia with MK features in
that it appears down-regulated 300-fold in TMD cells and
500-fold in both DS and non-DS AMKL compared with
normal MK samples (Tables 3 and 7). Finally, transcript
for MPL, the receptor of thrombopoietin which is the pri-
mary regulator of normal thrombopoiesis (the formation
of platelets) [53,73,76], is decreased by ~70% in either
TMD, DS and non-DS AMKL cells vs. normal MK cells.
Figure 4 Biological model of the transcriptome depicting progressive changes from MK to TMD then to DS AMKL. Downward pointing arrow
indicates the repression of genes involved in MK differentiation; upward pointing arrow indicates the over-expression of potential molecular markers of
progression to AMKL. Value: mean gene expression value normalized across all the pool samples. §Observed both in DS and non-DS AMKL.
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on chromosome 18 and encoding for the uncharacterized
membrane protein TMEM241 has been found in both DS
(59-fold) and non-DS (156-fold) AMKL cells vs. normal
MK. Although this probe was not present in all considered
experimental platforms, its extreme differential expression
makes it a candidate for further studies as a marker of
progression from normal MK to AMKL blasts, also due to
its 126-fold over-expression in TMD vs. MK cells.
Moreover, we identified several signatures of progression
specifically to DS AMKL. Remarkably, segments and genes
up- or down-regulated in TMD in comparison with nor-
mal MK cells were highly similar to those specifically
found in DS AMKL, underlining striking similarities be-
tween TMD and DS AMKL at the level of the whole tran-
scriptome (already noted in [21], in their smaller set). On
the other hand, a direct comparison between TMD and
DS AMKL shows specific potential markers of progression
to DS AMKL. As cited above, apolipoproteins genes
(APOC1, APOC2, APOE) have been described as asignature of progression from TMD to DS AMKL [20] and
it is interesting to notice that APOC2 is among the 20
most expressed genes in the comparison between TMD
and MK (25.88-fold increase), showing a progressive in-
crease of expression from normal MK to TMD and then
to DS AMKL. In our analysis, ZNF587B appears to be the
most discriminant marker between TMD and DS AMKL.
Again, this observation offers the opportunity to integrate
and discuss single genes and pathways previously de-
scribed as abnormally expressed in DS or non-DS AMKL
(Table 8). For example, the PRAME gene, encoding for a
tumor antigen [21] was identified as a specific marker for
DS AMKL blasts (n=7), with no expression in TMD (n=9).
While our meta-analysis on PRAME expression data
points (36 for DS AMKL and 11 for TMD) confirmed a
clear over-expression of PRAME in DS AMKL (4.2-fold in-
crease, Table 8), it was not the most discriminant
marker, that was exactly ZNF587B, while PRAME was
the 33rd out of 25,955 transcripts ordered by decreasing
DS AMKL vs. TMD expression ratio (Additional file 8).
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ginate from fetal hematopoietic cells [17,18,26,27] and the
progenitors (fetal/neonatal MKP) are present in the cord
blood [28,29], comparisons with CB MK cells have been
also performed. Data from DS and non-DS AMKL vs. CB
MK comparisons confirmed the repression of the clusters
of genes expressed in MK. The over-expression of a region
with collagen genes emerged both in DS and non-DS
AMKL as well as that of the single gene PTPRO (Table 5a
and 5b), encoding for a tyrosine phosphatase receptor
known to be involved in megakaryocytopoiesis and whose
mRNA targeting by antisense oligonucleotides results in
inhibited MK progenitor proliferation [77]. On the other
hand, the difference between DS and non-DS AMKL vs.
CB MK is shown by the over-expression of the two olfac-
tive receptor genes OR10A5 and OR10A4 (Table 4) only in
non-DS derived cells.
The analysis of enrichment in specific gene functions
using the tool FuncAssociate, for the 100 most over- or
under-expressed genes in the comparison of DS vs. non-
DS AMKL and of both of them vs. MK cells gave no sig-
nificant results, other than a significant enrichment in
genes involved in sequence-specific DNA-binding in
non-DS AMKL vs. MK cells (data not shown), highlight-
ing the relevance of remodeling the transcription factor
network in leukemia.Conclusions
Our results provide a systematic meta-analysis using any
available gene expression profile dataset related to AMKL
in pediatric age. These allow to identify more general
trends and to produce a highly coherent view of the tran-
scriptome depicting progressive changes from MK to
TMD and then to DS AMKL. We believe that the origin-
ality of our results is due to several concurrent original
features of the TRAM 1.1 platform. Advantages and rele-
vant differences are: integration of the largest possible
number of samples; integrated analysis of the largest pos-
sible number of genes (the integration of different plat-
forms led us to assess expression ratio for about 26,000
loci, quantitating almost 4,000 genes in addition to the
widely used platform U133A when used alone); absence of
a priori filtering (in several works, this led to actual ana-
lysis of less than 50% of the genes present on the experi-
mental platform); characterization at regional/map level in
the study of gene expression (usually absent in the works
from which data were obtained), relevant with regard to
the study of an aneuploidy such as trisomy 21.
These results provide a new integrated model of the
whole human transcriptome in DS and non DS AMKL,
TMD and normal human MK cells, providing hints about
pathophysiology of AMKL and also being useful to high-
light possible clinical markers.Additional files
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